FOLH1 and neoplasm: The predominant expression of PSMA on tumor vasculature emphasized [177Lu]Lu-PSMA-I&T’s capability to disrupt tumor-associated endothelial cells and reduce blood supply to the tumor, highlighting its potential therapeutic benefit [25].